Fr. 184.00

Prevention of Progression in Chronic Liver Disease - An Update on SNMC (Stronger Neo-Minophagen C). In honour of Hans Popper's 100th birthday

English · Hardback

Shipping usually within 6 to 7 weeks

Description

Read more

In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.

List of contents

List of Principal Authors.- Preface. Introduction.- 1: Mechanisms of fibrogenesis.- 2: Non-invasive markers of liver injury.- 3: Complications of cirrhosis: the relevance of hepatocellular carcinoma.- 4: Controlling necroinflammation of liver with SNMC (Stronger Neo Minophagen C): therapy on interferon non-responders.- 5: Predictive parameters of non-response to standard hepatitis treatment.- 6: Concepts for the treatment of non-responders in hepatitis.- 7: Glycyrrhizin: the molecule and present knowledge of action in various liver diseases.- 8: Dendritic cells in immune responses against hepatitis C virus.- 9: SNMC in the prevention of cirrhosis and hepatocellular carcinoma: Japanese experience.- 10: SNMC in interferon non-responders with chronic hepatitis C: European experience in controlled trials.- Index.

Summary

In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.

Product details

Assisted by Hiyashi (Editor), N Hiyashi (Editor), N. Hiyashi (Editor), M. P. Manns (Editor), M.P. Manns (Editor), P Manns (Editor), P Manns (Editor)
Publisher Springer Netherlands
 
Languages English
Product format Hardback
Released 14.04.2009
 
EAN 9780792387961
ISBN 978-0-7923-8796-1
No. of pages 130
Weight 376 g
Illustrations VIII, 130 p.
Series Falk Symposium
Falk Symposium
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

C, Medicine, INTERNAL MEDICINE, Hepatology, Biomedical and Life Sciences, Biomedicine, general, Biomedical Research, Clinical and internal medicine, koffie;hepatology

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.